Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes.

ABSTRACT:

Purpose

We explored the use of intraventricular ¹³¹I-Omburtamab targeting B7-H3 in patients with ETMR.

Methods

Patients were enrolled in an IRB approved, phase 1, 3 + 3 dose escalation trial. Patients with CNS disease expressing the antibody target antigen B7-H3 were eligible. We report on a cohort of three patients with ETMR who were enrolled on the study. Three symptomatic children (ages 14 months, 3 and 3.5 years) had large parietal masses confirmed to be B7-H3-reactive ETMR. Patients received 2 mCi ¹³¹I-Omburtamab as a tracer followed by one or two therapeutic ¹³¹I-Omburtamab injections. Dosimetry was based on serial CSF, blood samplings and region of interest (ROI) on nuclear scans. Brain and spine MRIs and CSF cytology were done at base

SUBMITTER: Bailey K 

PROVIDER: S-EPMC7416633 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature